Rhumbline Advisers Kal Vista Pharmaceuticals, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KALV
# of Institutions
121Shares Held
47.4MCall Options Held
71.8KPut Options Held
26.3K-
Vr Adviser, LLC New York, NY6.25MShares$71.3 Million8.08% of portfolio
-
Tang Capital Management LLC San Diego, CA4.22MShares$48.1 Million6.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$47.8 Million2.06% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$42.1 Million2.56% of portfolio
-
Capital World Investors Los Angeles, CA3.23MShares$36.8 Million0.01% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $281M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...